

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## Synthesis and Antiviral Activity of 5-Halovinyl-6-Aza-2'-Deoxyuridines

W. L. Mitchell<sup>a</sup>; P. Ravenscroft<sup>a</sup>; M. L. Hill<sup>a</sup>; L. J. S. Knutsen<sup>a</sup>; R. F. Newton<sup>a</sup>; D. I. C. Scopes<sup>a</sup>

<sup>a</sup> Chemical Research Department, Glaxo Group Research Ltd., England

**To cite this Article** Mitchell, W. L. , Ravenscroft, P. , Hill, M. L. , Knutsen, L. J. S. , Newton, R. F. and Scopes, D. I. C.(1985) 'Synthesis and Antiviral Activity of 5-Halovinyl-6-Aza-2'-Deoxyuridines', *Nucleosides, Nucleotides and Nucleic Acids*, 4: 1, 173 – 175

**To link to this Article:** DOI: 10.1080/07328318508077847

**URL:** <http://dx.doi.org/10.1080/07328318508077847>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ANTIVIRAL ACTIVITY OF 5-HALOVINYL-6-AZA-2'-DEOXYURIDINES

W. L. Mitchell, P. Ravenscroft, M. L. Hill, L. J. S. Knutsen,  
R. F. Newton and D. I. C. Scopes\*


Chemical Research Department, Glaxo Group Research Ltd., Ware,  
Hertfordshire, SG12 0DJ, England

Abstract: (E)-5-(2-bromovinyl)-6-aza-2'-deoxyuridine and some related analogues have been synthesized and evaluated for antiherpes activity.

During the 1960's 5-substituted 6-aza-2'-deoxyuridines received attention as potential antiviral and antitumour agents<sup>1,2</sup>. However, the nature of the 5-substitution was limited to halogen, methyl, hydroxymethyl and trifluoromethyl. The advent of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU; 1) as a potent and selective antiherpes agent<sup>3</sup> has led us to evaluate further 5-substituted 6-aza-2'-deoxyuridines as potential therapeutic agents. We now describe the synthesis and antiherpes activity of the novel (E)-5-(2-bromovinyl)-6-aza-2'-deoxyuridine (6-aza-BVDU; 2) and some closely related derivatives (3) - (6).


Our first synthesis of 6-aza-BVDU required (E)-5-(2-bromovinyl)-6-azauracil (8). Oxidation of 5-hydroxymethyl-6-azauracil to the carboxaldehyde (7) was accomplished using benzeneseleninic anhydride<sup>4</sup> [82%; THF, reflux]. Condensation of (7) with malonic acid [piperidine cat./ pyridine], followed by treatment with N-bromosuccinimide (NBS) [aq. KOAc, 60<sup>0</sup>] gave (8) in 30% overall yield from (7) [<sup>1</sup>H NMR[(CD<sub>3</sub>)<sub>2</sub>SO] δ 6.98 (d, J14Hz, HC=CHBr) and 7.7 (d, J14Hz, HC=CHBr)].

The trimethylsilyl derivative of (8) was condensed with 2-deoxy-3, 5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride [stannic chloride (1.1eq.), 1,2-dichloroethane, 25<sup>0</sup>] to afford an anomeric mixture of blocked 2'-deoxyribonucleosides (9) [34%; β:α=2:3]. Deprotection [NaOMe/methanol] followed by chromatographic separation of the anomers provided 6-aza-BVDU (2) [32%; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 6.38 (dd, J7,5Hz, 1'-H),



(1) X = CH (BVDU)

(2) X = N (6-aza-BVDU)




(3) X = Br, Y = F

(4) X = Cl, Y = H


(5) X = SMe, Y = H

(6) X = Y = Br



(7) R = CHO

(8) R = CH=CHBr




(9)


7.00 (d, J14Hz, CH=CHBr), and 7.69 (d, J14Hz, CH=CHBr)] and its  $\alpha$ -anomer (10) [40%;  $^1\text{H}$  NMR [(CD<sub>3</sub>)<sub>2</sub>SO]  $\delta$  6.27 (t, J6Hz, 1'-H), 7.06 (d, J14Hz, CH=CHBr), and 7.72 (d, J14Hz, CH=CHBr)].

The somewhat tedious separation of (2) and (10) directed us to adopt an alternative approach. This utilized the known 5-hydroxymethyl-2'-deoxy-6-azauridine (11)<sup>2</sup>, obtainable as its pure  $\beta$ -anomer. Oxidation of (11) with diphenyldiselenide-*t*-butylhydroperoxide<sup>5</sup> [benzene, reflux] afforded in 80% yield the carboxaldehyde (12), a versatile intermediate for our synthesis of 5-vinyl-6-aza-2'-deoxyuridines. Treatment of (12) with carbomethoxymethylenetriphenylphosphorane [CH<sub>3</sub>CN, reflux] effected smooth (85%) conversion to the  $\alpha,\beta$ -unsaturated ester (13). Hydrolysis of the ester with concomitant deblocking of the sugar residue [82%; KOH, methanol] afforded (14). Subsequent brominative decarboxylation of (14) [36%; NBS, aq. KOAc, 60<sup>0</sup>] gave anomerically pure 6-aza-BVDU (2). The  $\beta$ -configuration of (2) was confirmed by the n.o.e. difference method<sup>6</sup>.


The corresponding fluoro-substituted system (3) was obtained via a similar strategy. Wadsworth-Emmons reaction of (12) [78%; (EtO)<sub>2</sub>P(=O)-



(10)


(11) R = CH<sub>2</sub>OH

(12) R = CHO



(13) R = Tol, R' = Me

(14) R = R' = H



(15) R = Tol, R' = Et

(16) R = R' = H

CHFCO<sub>2</sub>Et, NaH, THF, 20<sup>0</sup>] afforded the fluoroacrylates (15) as a mixture of E:Z isomers (1:1), hydrolysis of which [86%; KOH, aq. methanol] gave the acids (16). Treatment of the latter compounds with NBS [aq. KOAc, 100<sup>0</sup>] provided a 20% yield of (3) after chromatography. Wittig reaction of (12) with chloromethylenetriphenylphosphorane in THF gave a 1:1 mixture of E:Z isomers (81%) which were deprotected [51%, K<sub>2</sub>CO<sub>3</sub>, MeOH] and separated to provide the chlorovinyl analogue (4). Similar schemes employing methylthiomethylene- and dibromomethylenetriphenylphosphoranes afforded (5) (9%) and (6) (55%), respectively, from (12).

In the plaque reduction assay (2) showed modest activity vs. HSV-1 (IC<sub>50</sub>=8μg/ml), about 1000 fold less potent than BVDU, and weak activity vs. HSV-2 (IC<sub>50</sub>=190μg/ml). The α-anomer (10) was inactive against these viruses. The chlorovinyl analogue (4) showed a similar profile of activity: IC<sub>50</sub>=20μg/ml vs. HSV-1, IC<sub>50</sub>=215μg/ml vs. HSV-2.

#### ACKNOWLEDGEMENTS

Antiviral screening was conducted by Drs. J. M. Cameron and J. A. V. Coates, Glaxo Group Research Ltd., Greenford. We thank Dr. G. Klinkert for <sup>1</sup>H NMR spectral data.

#### REFERENCES

1. Shen, T. Y., Ruyle, W. V. and Bugianesi, R. L., J. Heterocycl. Chem., 1965, 2, 495; Pliml, J., Prystas, M. and Sorm, F., Collect Czech. Chem. Commun., 1963, 28, 2588; Shiau, G. T. and Prusoff, W. H., Carbohydr. Res., 1978, 62, 175; Mertes, M. P., Saheb, S. E. and Miller D., J. Heterocycl. Chem., 1965, 2, 493; Dipple, A. and Heidelberger, C., J. Med. Chem., 1966, 9, 715.
2. Bobek, M., Farkas, J. and Sorm, F., Collect. Czech. Chem. Commun., 1967, 32, 3581.
3. De Clercq, E., Descamps, J., De Somer, P., Barr, P. J., Jones, A. S. and Walker, R. T., Proc. Natl. Acad. Sci. U.S.A., 1979, 76, 2947.
4. Barton, D. H. R., Brewster, A. G., Hui, R. A. H. F., Lester, D. J., Ley, S. V. and Back, T. G., J.C.S. Chem. Commun., 1978, 952.
5. Kuwajina, I., Shimizu, M. and Urabe, H., J. Org. Chem., 1982, 47, 837.
6. Knutsen, L. J. S., Newton R. F., Scopes, D. I. C. and Klinkert, G., Carbohydr. Res., 1982, 110, C5.